Differentiation in myelodysplastic, myeloid leukaemic and normal haemopoietic cells: a new approach exploiting the synergistic interaction between differentiation inducers and DNA synthesis inhibitors.
D000970:Antineoplastic Agents / Q000494:pharmacology; D016590:Aphidicolin; D001853:Bone Marrow / Q000473:pathology; D001854:Bone Marrow Cells; D002454:Cell Differentiation / Q000187:drug effects; D002478:Cells, Cultured; D003561:Cytarabine / Q000494:pharmacology; D004261:DNA Replication / Q000187:drug effects*; D004224:Diterpenes / Q000494:pharmacology; D005559:Formamides / Q000494:pharmacology; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000378:metabolism; D006801:Humans; D007951:Leukemia, Myeloid / Q000378:metabolism / Q000473:pathology*; D015122:Mercaptopurine / Q000494:pharmacology; D009196:Myeloproliferative Disorders / Q000378:metabolism / Q000473:pathology*; D012016:Reference Values; D014212:Tretinoin / Q000494:pharmacology
D000970:Antineoplastic Agents; D004224:Diterpenes; D005559:Formamides; D003561:Cytarabine; D016590:Aphidicolin; D014212:Tretinoin; D015122:Mercaptopurine; C002950:methylformamide